Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease

NCT02782741 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

Glycogen Storage Disease Type II;Pompe's Disease

Interventions

DRUG: Avalglucosidase alfa (GZ402666)
DRUG: Alglucosidase alfa (GZ419829)

Sponsor

Genzyme, a Sanofi Company